September 2011
by Ed Silverman
WCC President Dr. Richard Walovitch, along with thought leaders from Drexel University, Merck & Co. and Icon Medical Imaging, share their thoughts on how the approval of imaging agents can enable earlier diagnosis of Alzheimer’s disease and potentially pave way to better therapies in a feature on “Solutions for Clinical Trial Imaging – Central Nervous System” in the September 2011 issue of R&D Directions (pg 42-43). In his discussion, Walovitch specifically shares his viewpoints on the value that imaging biomarkers can play in detecting the risk of Alzheimer’s and other forms of dementia at the preclincial stage, when drug therapies have the potential to be most effective. (Subscription required)
